Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 58, No 4 (2007)
Review paper
Submitted: 2013-02-15
Published online: 2007-05-17
View PDF (Polish) Download PDF file
Get Citation

Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly

Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyżanowska-Świniarska, Andrzej Lewiński, Elżbieta Łomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyński
Endokrynol Pol 2007;58(4):350-353.

open access

Vol 58, No 4 (2007)
Reviews — Postgraduate Education
Submitted: 2013-02-15
Published online: 2007-05-17

Abstract

Consensus statement of the Polish Society of Endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then 30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets: biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction, inhibition of tumor growth). The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow objective evaluation of long-term efficacy of the treatment.
(Pol J Endocrinol 2007; 58 (4): 350-355)

Abstract

Consensus statement of the Polish Society of Endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then 30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets: biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction, inhibition of tumor growth). The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow objective evaluation of long-term efficacy of the treatment.
(Pol J Endocrinol 2007; 58 (4): 350-355)

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

acromegaly; somatostatin analogs; preparation to the surgery

About this article
Title

Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly

Journal

Endokrynologia Polska

Issue

Vol 58, No 4 (2007)

Article type

Review paper

Pages

350-353

Published online

2007-05-17

Page views

549

Article views/downloads

1176

Bibliographic record

Endokrynol Pol 2007;58(4):350-353.

Keywords

acromegaly
somatostatin analogs
preparation to the surgery

Authors

Marek Bolanowski
Ewa Bar-Andziak
Beata Kos-Kudła
Barbara Krzyżanowska-Świniarska
Andrzej Lewiński
Elżbieta Łomna-Bogdanov
Andrzej Milewicz
Jerzy Sowiński
Wojciech Zgliczyński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl